The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we sought to broadly survey cancers to identify those in which the microbiome may play a prognostic role using retrospective analyses of patients with advanced cancer treated with ICIs. | Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors Causal modeling timing and classes of concomitant medications
